ESH Video

ESH International Conference MYELOPROLIFERATIVE NEOPLASMS

ESH International Conference MYELOPROLIFERATIVE NEOPLASMS
September 30 - October 02, 2010 - Albufeira, Portugal
Chairs :

Information

Over the past few years there has been a flood of new insights into the classification,pathogenesis and management of the myeloproliferative neoplasms. This meeting is essentially a workshop with an audience. It brings together scientists and clinicians with new data on the cellular and molecular biology of these disorders as well as their diagnosis and treatment.

Programme

Thursday, September 30, 2010

Session I - Chair: T. Green
17h30 Welcome T. Green (Cambridge, UK)
17h35 "TK inhibitors - lessons from CML for the MPNs" J. Goldman (London)
18h00 Recombinant interferon alpha may retard progression of early primary myelofibrosis (PM) by reducing splenetically and by changing marrow morphology: results in 18 patients R. Silver (New York)
18h25 Molecular basis of refractory anemia with ringed sideroblasts and marked thrombocytosis M. Cazzola (Pavia)
18h50 The genomics of the myeloproliferative disorders P. Campbell (Cambridge, UK)
19h15 Clonal evolution of MPN R. Skoda (Basel)
19h40

Finish

20h00 Cocktails and Dinner

Friday, October 1, 2010

Session II - Chair: T. Barbui
08h30 Stem cell trafficking in primary myelofibrosis

R. Hoffman (New York)

08h55 NF-E2 overexpression in vivo: a murine model of myeloproliferative disorders H.L. Pahl (Freiburg)
09h20 Derangement of endotheliopoiesis in myeloproliferative neoplasms G. Barosi (Pavia)
09h45 Modeling the human 8p11-myeloproliferative neoplasms syndrome in immuno-deficient mice Helena Agestarm (Lund)
10h00 The myeloproliferative neoplasm-associated JAK2 V617F kinase is not endosomally sorted by SOCS3 Joanne Elliott ( Belfast)
10h15

TEA

10h45 Molecular pathogenesis of the myeloproliferative neoplasms

T. Green (Cambridge, UK)

11h10 Genetic instability in myeloproliferative disorders

W. Vainchenker (Paris)

11h35 MicroRNAs abnormalities in the myeloproliferative neoplasms A. Vannucchi (Florence)
12h00 The Dominant Negative b Isoform of the Glucocorticoid Receptor is Uniquely Expressed in Erythoid Cells Expanded from Patients with Polycythemia Vera Anna Rita Migliaccio
12h15 Lnk contrains Myeloproliferative Disease (MPD) Development Wei Tong (Philadelphia)
12h30 LUNCH & POSTERS
Session III - Chair: W. Vainchenker
17h45 An update on INCB018424, an oral JAK1/2 inhibitor, as therapy for myelofibrosis

S. Verstovsek (MD Anderson, USA)

18h10 Biomarkers of inflammation and thrombosis in myeloproliferative neoplasms T. Barbui (Bergamo)
18h35 Jak2 V617F mutation in PV, is that the whole story?

J. Prchal (Utah)

19h00 Signalling pathways in myeloproliferative disorders

M.-F. McMullin (Belfast)

19h25 Finish
20h00 Dinner

Saturday, October 2, 2010

Session IV - Chair: H. Pahl
08h30 Phenotype and genotype in the chronic myeloproliferative disorders J. Spivak (Baltimore)
08h55 S. Constantinescu (Brussels)
09h20 New genes, new drugs, new data about old drugs: time to change MPD management?

J.-J. Kiladjian (Paris)

09h45 Competitive potential of JAK2-V617F Stem Cells Pontus Lundberg (Basel)
10h00 JAK2 V617F induced TNF resistance as a mechanism of clonal expansion in myeloproliferative neoplasm Angela Fleischman (Portland)
10h15

TEA

10h45 Molecular pathogenesis and therapy of essential thrombocythemia and primary myelofibrosis R. Levine (Boston)
11h10 New prognositic models to predict prognosis in MPN F. Passamonti (Pavia)
11h35 Deciphering the genetic complexity of myeloproliferative neoplasms R. Kralovics (Vienna)
12h00 STAT5A over-expression induces hematopoietic exhaustion not only in transduced hematopoietic stem cells but also to non-transduced normal hematopoietic stem cells of primary myelofibrosis mouse Skin Kaneko (Tokyo)
12h15 A phase II trial with RAD001 in myelofibrosis: results of an ancillary biological protocol Paola Guglielmelli (Florence)
12h30 LUNCH & POSTERS
Session V - Chair: R. Skoda
14h00

Comparing the impact of current and new therapies on patients with myelofibrosis

R. Mesa (Mayo Clinic, USA)

14h25 Function of TET2 in normal and malignant hematopoiesis O. Bernard (Paris)
14h50 tbc
15h00 Mutations associated with acquired uniparental disomy in MPN N. Cross (Salisbury, UK)
15h15 Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukemia V. Najfeld (New York)
15h30 Implication of the hemangioblast in the pathogenesis of myelofibrosis I. Triviai (Hamburg)
15h45

TEA

16h15

Animal models of MPN

J.-L. Villeval (Paris)

16h40 Intracellular signaling patterns correlate with cellular and disease phenotype in human myeloproliferative neoplasms

B. Huntly (Cambridge)

17h05

Mutations associated with acquired uniparental disomy in MPN

N. Cross (Southampton, UK)
17h30 MANNED POSTER SESSION WITH REFRESHMENTS
19h00

Finish

20h00

Conference Dinner

Abstract submission

Symposia

Accommodation

Venue

Grande Real Santa Eulália
Praia de Santa Eulália
PO Box 2445 Albufeira

Corporate partners

Scholarship

Workshop

Registration